USA flag logo/image

An Official Website of the United States Government

SHIKIMATE ENZYMES AS NOVEL TUBERCULOSIS DRUG TARGETS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
45555
Program Year/Program:
1999 / SBIR
Agency Tracking Number:
1R43AI046094-01
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
SEQUELLA, INC.
9610 MEDICAL CENTER DR, STE 200 ROCKVILLE, MD -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1999
Title: SHIKIMATE ENZYMES AS NOVEL TUBERCULOSIS DRUG TARGETS
Agency: HHS
Contract: N/A
Award Amount: $294,182.00
 

Abstract:

Not Available The development of equipment that requires extensive fluid manipulation, such as analytical diagnostic tools, has generally lagged behind those of a purely electromechanical nature, even though obvious demand exists in areas as diverse as medicine, environmental monitoring, food safety, and counter-terrorism. We propose a self-contained, miniaturized bioassay system that is capable of simultaneously detecting and quantifying the presence of 6 to 10 analytes in a single sample of less than 500 microliters volume. Such a diagnostic device has clear applicability to many industrial, medical and military sectors. This handheld, multi-analyte, wet-chemistry diagnostic system will measure diverse water-borne analytes at concentrations ranging to below one part per billion. The system will be constructed by the integration of state-of-the-art digital and analog circuitry with novel miniaturized fluid handling technologies, optics, and highly specific antibody-based assay techniques. All analyte-specific assay components will be incorporated in a disposable molded plastic coupon, allowing the system to detect and quantify a wide range of chemicals, proteins, viruses, bacteria and biological fragments by simply changing coupons. The proposed system allows coupon re-use until a strong positive showing occurs, greatly reducing costs in applications such as counter-terrorism where most measurements will produce negative responses. BENEFITS: Environmental, medical and public safe

Principal Investigator:

Jan Dijkstra

Business Contact:


3017627776
CAROLNACY@SEQUELLA.COM
Small Business Information at Submission:

SEQUELLA, INC.
9610 MEDICAL CENTER DR, STE 200 ROCKVILLE, MD 20850

EIN/Tax ID: 522044703
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No